Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,353 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Positron emission tomography Clear all

Conditions: Brown Adipose Tissue
Interventions: PET imaging; Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Ventricular Tachycardia, Arrhythmia
Interventions: 123I-metaiodobenzylguanidine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson Disease
Interventions: [11C]-CS1P1; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chest Pain, Angina Pectoris, Myocardial Infarction
Interventions: coronary artery computed tomography angiogram, single photon emission computed tomography; Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 25 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Esophageal Cancer
Interventions: Radiation, FMISO PET CT; Radiation · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cancer
Interventions: [18F]F-AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson's Disease
Interventions: DNA/GeneticTesting, FDG PET scan, MRI scan, Clinical and neuropsychological assessments; Genetic · Radiation · Other
Lead sponsor: Northwell Health; Other
Eligibility: 40 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Complex Regional Pain Syndrome, Sciatica
Interventions: [18F]-FTC-146; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Central Nervous System Tumor, Head and Neck Neoplasms
Interventions: L-(11C) methionine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Alzheimer's Disease (AD)
Interventions: [18F]T807; Drug
Lead sponsor: Molecular NeuroImaging; Other
Eligibility: 20 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions: 18F-rhPSMA-7.3, PET/CT; Drug · Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care; Drug · Combination Product
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Albany, Georgia • Atlanta, Georgia • Augusta, Georgia + 4 more

Conditions: Down Syndrome, Amyloid Beta-protein
Interventions: Florbetaben (BAY94-9172); Drug
Lead sponsor: Lantheus Biosciences Ltd.; Industry
Eligibility: 21 Years and older
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Sun City, Arizona • New Haven, Connecticut

Conditions: Melanoma (Skin)
Interventions: iodinated contrast dye, computed tomography, positron emission tomography, fludeoxyglucose F 18; Drug · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
Interventions: Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan; Biological · Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: 18F-FGLN PET Imaging, (18F)FPGLU; Diagnostic Test · Drug
Lead sponsor: Stephen Y. Chan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cardiovascular Diseases
Interventions: L-NAME, L-Arginine, Phenylephrine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Edodekin alfa, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 27
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 16 more

Conditions: Depression
Interventions: 11C-MCI, 11CPS13; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dosimetry, Pharmacokinetics
Interventions: [11C]LY2428703; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography, Docetaxel, PSMA PET Scan, Single Photon Tomography and Computed Tomography Scan, Biospecimen Collection; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Brain Metastases
Interventions: 18F fluciclovine; Drug
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 15 more

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Cigarette Smoking, Computed Tomography, Positron Emission Tomography, Questionnaire Administration; Behavioral · Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Relatlimab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 90
States / cities: Dublin, California • Fremont, California • Fresno, California + 69 more

Search by objective public record fields.

The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue

Imaging With a Radio Tracer to Guide VT Ablations

CS1P1 PET Studies of Neuroinflammation in Parkinson Disease

Study of Coronary Artery Computed Tomography to Diagnose Emergency Chest Pain

Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

Genotypic Influences on Network Progression in Parkinson's Disease

[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica

Expanded Access [11C] Methionine PET Imaging

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

PET Image in PAH Patients

Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)

Imaging of Brain Receptors Using (11C)mGlu1

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer